Eccogene Announces Positive Phase 1 Data for Oral THR-ß Full Agonist and Oral SSAO Inhibitor in Late-Breaking Poster Presentations at the American Association for the Study of Liver Diseas...
Thermo Fisher Scientific Inc (TMO)
Last thermo fisher scientific inc earnings: 4/22 06:00 am
Check Earnings Report
US:NYSE Investor Relations:
ir.thermofisher.com/investors/investor-overview/default.aspx
Company Research
Source: Yahoo! Finance
BOSTON and SHANGHAI, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced that two late-breaking abstracts on new Phase 1 data covering its novel oral THR-ß full agonist (ECC4703) and oral SSAO inhibitor (ECC0509) will be reviewed in poster presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting ® . The congress is taking place November 15-19 in San Diego, California. “We are pleased that our Phase 1 results for ECC4703 and ECC0509 were selected as late-breaking abstracts at this premier medical congress – the first time human data for these programs will be publicly presented,” said Jingye Zhou, Chief Executive Officer of Eccogene. “Our Phase 1 results – which demonstrate favorable safety and tolerability profiles, PK and PD profiles supporting a once daily dose, and clear
Show less
Read more
Impact Snapshot
Event Time:
TMO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TMO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TMO alerts
High impacting Thermo Fisher Scientific Inc news events
Weekly update
A roundup of the hottest topics
TMO
News
- Clinical Trial Supply and Logistics Market Size Expected to Reach USD 8.58 Bn by 2034 [Yahoo! Finance]Yahoo! Finance
- Mesenchymal Stem Cells (MSC) Market Set to Surpass USD 9.72 Billion by 2032 | The Role of Biopharma Collaborations in Accelerating Growth [Yahoo! Finance]Yahoo! Finance
- End Market Growth, New Acquisitions Drive Thermo Fisher's Shares [Yahoo! Finance]Yahoo! Finance
- Mass Spectrometry Market Projected to Surpass USD 11.25 Billion by 2032 at a 7.74% CAGR, Driven by Rising Demand in Pharmaceutical and Environmental Applications - SNS Insider [Yahoo! Finance]Yahoo! Finance
- Cell Freezing Media Market Size To Worth USD 333.29 Billion by 2032 | CAGR of 9.15% [Yahoo! Finance]Yahoo! Finance
TMO
Earnings
- 10/23/24 - Beat
TMO
Sec Filings
- 11/12/24 - Form 4
- 11/8/24 - Form 144
- 11/8/24 - Form 4
- TMO's page on the SEC website